CTIS2024-511886-12-00Active, not recruitingPhase 1
Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study - 2020-004195-17
I.F.O. Istituti Fisioterapici Ospitalieri0 sites146 target enrollmentStarted: February 15, 2024Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Enrollment
- 146
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- Male
Inclusion Criteria
- •Histologically proven prostate adenocarcinoma - IR or HR in the NCCN definition - N0M0 at staging with choline or (preferably) PSMA PET-CT; - ECOG performance status between 0 and 2;
Exclusion Criteria
- •T3b disease according to the 8th AJCC classification; - PSA>20 ng/ml at any time point - Gleason Score of 9 or 10 (Grade Grouping V) - Previous local treatment of the prostate with surgery (radical prostatectomy or cryotherapy) - Previous radiotherapy to the pelvis - Previous chemotherapy for malignancy in past 5 years - Impossibility to implant fiducials for tracking purposes - Impossibility to undergo MRI of the prostate - Contraindication to short term AD - Prostate volume >90cc
Investigators
Similar Trials
Recruiting
Phase 2
Sbrt±sTad for Unfavorable iNtermediate rIsk/high-risk prostate cancer (STUNNIN): A Randomized Phase II Study2024-511886-12-00I.F.O. Istituti Fisioterapici Ospitalieri146
Completed
Phase 3
Adjuvant GIST TrialACTRN12605000712606AGITG400
Active, not recruiting
Phase 1
Intermediate and high risk localized , completely resected, gastrointestinal stromal tumors ( GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate ( Glivec) versus no further therapy after complete surgery.To assess whether mesylate, as an adjunct to complete surgery, is able to improve prognosis of patients with intermediate and high risk localized GIST.EUCTR2004-001810-16-ESEORTC908
Active, not recruiting
Phase 1
Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgeryEUCTR2004-001810-16-BEEuropean Organisation for Research and Treatment of Cancer900
Active, not recruiting
Phase 1
Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgeryGastrointestinal stromal tumors (GIST) are mesenchymal neoplasms usually arising from the gastrointestinal wall. Pathologically,they present with spindle cells in most cases. Immunohistochemically, GIST cells are almost always positive for CD117.CD117 corresponds to the KIT receptor, a tyrosine kinase receptor which is altered in GIST due to a mutation to the c-kit oncogene. This event is held to be critical for GIST pathogenesis.MedDRA version: 14.1Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-001810-16-DEEuropean Organisation for Research and Treatment of Cancer900